<DOC>
	<DOCNO>NCT01392170</DOCNO>
	<brief_summary>The goal clinical research study learn add pegylated interferon-alfa 2a ( Pegasys ) TKI already receive help control CML . The safety treatment combination also study . Pegasys form drug interferon . It design help body 's immune system fight infection . It may also affect body 's response cancer . A TKI ( imatinib mesylate , nilotinib , dasatinib ) design bind shut protein tumor cell call Bcr-Abl . Shutting Bcr-Abl may prevent CML cell grow , may cause die . You already receive TKI . This consent form describe administration Pegasys , test procedure need perform receive Pegasys , risks/benefits may receive Pegasys .</brief_summary>
	<brief_title>Pegasys Patients With Chronic Myeloid Leukemia ( CML )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , receive Pegasys needle skin 1 time week study . You teach use study drug first visit administer future dos . You continue receive TKI already take dose frequency receive begin take part study . Study Visits : At every study visit , ask side effect may list drug may take . Every 1-2 week 8 week , every 6-8 week , blood ( 1-2 teaspoon ) draw routine test . Every 3 month 6 month , every 6-12 month , complete physical exam , include measurement vital sign . Every 3-6 month 1 year , bone marrow aspirate check status disease check change chromosome . Every 3-6 month 1 year , every 6-12 month , blood ( 1 teaspoon ) drawn check level leukemia blood . Length Study : You may continue take Pegasys long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . This investigational study . Pegasys FDA approve commercially available treatment CML . TKIs ( imatinib , nilotinib , dasatinib ) FDA approve commercially available treatment CML . The combination drug treat CML investigational . Up 50 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Patients 16 year old Philadelphia chromosome ( Ph ) positive BCRABL1positive CML ( determine cytogenetics , FISH , PCR ) . 2 . Patients receive FDAapproved TKI management CML . 3 . Patients must receive TKI therapy least 24 month increase TKI dose last 6 month . 4 . Patients must complete cytogenetic remission . 5 . Patients must detectable BCRABL1 transcript level meet least one follow criterion : 1 . The patient receive therapy least 2 year sustain major molecular response , 2 . The patient receive therapy least 5 year sustain complete molecular response . 6 . Patients must know continuous interruption TKI therapy great 14 consecutive day total 6 week 6 month prior enrollment . 7 . Patients must sign informed consent indicate aware investigational nature study . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 . 9 . Adequate organ function define : bilirubin &lt; 2x upper limit normal ( ULN ) ( unless associate Gilbert 's syndrome ) , creatinine &lt; /= 1.5x ULN , serum glutamate pyruvate transaminase ( sGPT ) serum glutamate oxaloacetate transaminase ( sGOT ) &lt; /= 2.5x ULN . 10 . Men woman childbearing potential practice effective method contraception . Women childbearing potential must negative serum urine pregnancy test within 1 week enrollment . 1 . Patients receive nonFDA approve TKI . 2 . Patients pregnant breastfeeding . 3 . Patients clinically significant heart disease ( NYHA Class III IV ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Tyrosine Kinase Inhibitors</keyword>
	<keyword>TKI</keyword>
	<keyword>Complete cytogenetic remission</keyword>
	<keyword>CCyR</keyword>
	<keyword>Minimal residual disease</keyword>
	<keyword>MRD</keyword>
	<keyword>PEG-IFNa-2a</keyword>
	<keyword>Pegasys</keyword>
	<keyword>Peginterferon Alpha-2a</keyword>
	<keyword>Philadelphia chromosome ( Ph ) -positive</keyword>
	<keyword>BCR-ABL1-positive</keyword>
</DOC>